Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDOP vs CHOP in Newly Diagnosed PTCL
NCT03952572Phase 3Unknown
- Sponsor
- Peking University
- Start
- May 2019
- Primary completion
- Apr 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Peking University. Primary endpoint: Response rate at 2 years. Status: unknown.
02
Drugs
doxorubicin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03952572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952572.